TRAM@PPF

TRAM@PPF is a targeted nanodrug delivery system designed for the treatment of pancreatic ductal adenocarcinoma (PDAC). It consists of the small molecule KCa3.1 channel inhibitor, TRAM-34, encapsulated within a poly(lactic-co-glycolic acid) (PLGA) nanoparticle core. The surface of the nanoparticle is modified with polyethylene glycol (PEG) and folic acid (FA) ligands (PEG2000-FA) to facilitate long circulation and active targeting of folate receptors, which are frequently overexpressed in PDAC cells. By specifically delivering TRAM-34 to the tumor site, TRAM@PPF aims to inhibit the oncogenic KCa3.1 channel, thereby suppressing tumor progression while minimizing systemic toxicity. Research on this system has been conducted by several Chinese institutions, including Chongqing University Jiangjin Hospital and China Pharmaceutical University, with preclinical efficacy demonstrated in mouse models.

Other names

TRAM-34-loaded PLGA-PEG-FA nanoparticlesTRAM34-loaded PLGA-PEG-FA nanoparticlesTRAM 34-loaded PLGA-PEG-FA nanoparticlesTRAM-34 encapsulated in PLGA-PEG2000-FA nanoparticlesTRAM34 encapsulated in PLGA-PEG2000-FA nanoparticlesTRAM 34 encapsulated in PLGA-PEG2000-FA nanoparticles